All News Editas Medicine, Inc.

Equities

EDIT

US28106W1036

Market Closed - Nasdaq Other stock markets 01:30:00 11/05/2024 am IST			5-day change	1st Jan Change
5.32 ^USD	-4.32%		-6.17%	-47.48%

09/05	Barclays Adjusts Editas Medicine Price Target to $9 From $11, Maintains Equal Weight Rating	MT
09/05	Morgan Stanley Upgrades Editas Medicine to Equal-Weight From Underweight	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting	10/05	GL
Barclays Adjusts Editas Medicine Price Target to $9 From $11, Maintains Equal Weight Rating	09/05	MT
Morgan Stanley Upgrades Editas Medicine to Equal-Weight From Underweight	09/05	MT
Transcript : Editas Medicine, Inc., Q1 2024 Earnings Call, May 08, 2024	08/05
Editas: Q1 Earnings Snapshot	08/05	AQ
Editas Medicine Announces First Quarter 2024 Results and Business Updates	08/05	GL
Editas Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events	02/05	GL
Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration	01/05	MT
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration	01/05	GL
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration	01/05	CI
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting	23/04	GL
Editas Medicine : April 2024 Corporate Presentation	12/04	PU
Editas Medicine : Corporate Effectiveness Report April 2024	12/04	PU
Transcript : Editas Medicine, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 02:05 PM	13/03
Barclays Adjusts Price Target on Editas Medicine to $11 From $10, Maintains Equal-Weight Rating	29/02	MT
Transcript : Editas Medicine, Inc., Q4 2023 Earnings Call, Feb 28, 2024	28/02
Editas: Q4 Earnings Snapshot	28/02	AQ
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates	28/02	GL
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates	28/02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Editas Medicine, Inc.

Equities

EDIT

US28106W1036

All News

Filters